Used in the pharmaceutical industry as a key intermediate in the synthesis of protease inhibitors, particularly in the development of antiviral drugs targeting hepatitis C virus (HCV). Its complex stereochemistry enables high selectivity and binding affinity to the NS3/4A protease enzyme, making it valuable in creating potent direct-acting antivirals (DAAs). The compound's structure supports improved metabolic stability and bioavailability in final drug formulations. It is also explored in research settings for optimizing drug candidates with enhanced resistance profiles and reduced side effects.